Zydus Lifesciences share price up marginally in the opening trade on August 14 after the company received zero observation from the United States Food and Drug Administration (USFDA) after inspection at Ahmedabad facility.
At 09:18am, Zydus Lifesciences was quoting at Rs 995.50, up Rs 6.45, or 0.65 percent, on the BSE.
The USFDA conducted an inspection at the group’s formulation manufacturing plant located SEZ – II, Ahmedabad.
The pre-approval inspection (PAI) conducted between August 11-13 for three products with general cGMP and concluded with NIL observations.
Also, USFDA conducted a surveillance inspection at the group’s formulation manufacturing plant located at Baddi in Himachal Pradesh, between August 4 to August 13, 2025.
The inspection concluded with 4 observations and there were no data integrity related observations, it added.
Catch all the market action on our live blog
The company's net profit increased 3.3% year-on-year to Rs 1,466.8 crore and revenue from operations grew by 5.9% to Rs 6,573.7 crore.
Earlier in this month, company received final approval from the USFDA for Diltiazem Hydrochloride Tablets USP, in strengths of 30 mg, 60 mg, 90 mg, and 120 mg.
The company also received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg, a first NOC approval in Canada.
Also Read - Zydus Lifesciences: Time to accumulate the stock?
In the month of July, the company completed the acquisition of Amplitude Surgical and holds 85.6% of the share capital and voting rights of Amplitude Surgical.
Also, company received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.
In the month of June, the company received two observations from US Food and Drug Administration (USFDA) post inspection conducted between June 9-18 at its oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad.
Brokerage Call
Prabhudas Lilladher has maintained ‘Accumulate’ rating with target price of Rs 970.
Motilal Oswal keeps 'neutral' rating on the stock with a target of Rs 1,000.
The share touched a 52-week high of Rs 1,218.60 and a 52-week low of Rs 797.05 on 22 August, 2024 and 07 April, 2025, respectively.
Currently, the stock is trading 18.31 percent below its 52-week high and 24.9 percent above its 52-week low.
The market capitalisation of the company stands at Rs 100,170.59 crore.
The share price slipped more than 15 percent in the last one-year.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
